Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dodick

Showing results (511-520 of 621) with videos related to

Pageof 63
Sort By:
Plos One|July 12, 2018
Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomesBing Si, Gina Dumkrieger, Teresa Wu, et al.
Neurology|August 17, 2022
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe PainRichard B Lipton, David W Dodick, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|March 9, 2011
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineDavid J Hewitt, Sheena K Aurora, David W Dodick, et al.
Lancet (London, England)|November 28, 2008
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialTony W Ho, Michel D Ferrari, David W Dodick, et al.
Brain : a Journal of Neurology|July 15, 2010
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggersMilena De Felice, Michael H Ossipov, Ruizhong Wang, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Cephalalgia : an International Journal of Headache|December 3, 2020
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extensionRichard B Lipton, Stewart J Tepper, Stephen D Silberstein, et al.
Headache|October 13, 2022
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycleDavid W Dodick, Andrew M Blumenfeld, Rashmi B Halker Singh, et al.
Headache|April 1, 2022
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative reviewDavid W Dodick, Peter J Goadsby, Messoud Ashina, et al.
Pageof 63

Showing results (511-520 of 621) with videos related to

Sort By:
Pageof 63
Plos One|July 12, 2018
Sub-classifying patients with mild traumatic brain injury: A clustering approach based on baseline clinical characteristics and 90-day and 180-day outcomesBing Si, Gina Dumkrieger, Teresa Wu, et al.
Neurology|August 17, 2022
Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe PainRichard B Lipton, David W Dodick, Peter J Goadsby, et al.
Cephalalgia : an International Journal of Headache|December 9, 2024
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysisB Lee Peterlin, Dale S Bond, Jessica Ailani, et al.
Cephalalgia : an International Journal of Headache|March 9, 2011
Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraineDavid J Hewitt, Sheena K Aurora, David W Dodick, et al.
Lancet (London, England)|November 28, 2008
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trialTony W Ho, Michel D Ferrari, David W Dodick, et al.
Brain : a Journal of Neurology|July 15, 2010
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggersMilena De Felice, Michael H Ossipov, Ruizhong Wang, et al.
Neurology|August 28, 2024
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME TrialRichard B Lipton, Andrea M Harriott, Julia Y Ma, et al.
Cephalalgia : an International Journal of Headache|December 3, 2020
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a <i>post-hoc</i> analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extensionRichard B Lipton, Stewart J Tepper, Stephen D Silberstein, et al.
Headache|October 13, 2022
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycleDavid W Dodick, Andrew M Blumenfeld, Rashmi B Halker Singh, et al.
Headache|April 1, 2022
Challenges and complexities in designing cluster headache prevention clinical trials: A narrative reviewDavid W Dodick, Peter J Goadsby, Messoud Ashina, et al.
Pageof 63